Shuntaro Obi

7PUBLICATIONS
3CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursMedical ethicsTime series and spatial modellingMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Apr 19, 2026
Is triple therapy redefining first-line treatment in intermediate-advanced hepatocellular carcinoma?

|Aug 02, 2025
Reply to letter to the editor "Comment on: "Hepatic immune-related adverse event increased the overall survival of patients with malignancies treated with immune checkpoint inhibitors"".

Tatsuo Kanda, Kaori Matsumoto, Shuntaro Obi

|Jul 08, 2025
Reply to Letter to the Editor "Hepatic irAE, ICI continuation, and survival: need for robust evidence beyond initial observations".

Tatsuo Kanda, Kaori Matsumoto, Shuntaro Obi

|Feb 29, 2024
Nomograms should be noted.

Shuntaro Obi, Masao Omata

|Feb 22, 2023
The incidence of all organ malignancies and overall survival of patient with sustained virological response of HCV-comparable to SMR (standardized mortality ratio) of Japan general population.

Shuntaro Obi, Miho Kanda, Yoshihiko Ooka

|May 28, 2021
Liver dysfunction of Atezolizumab + Bevacizumab -a matter of life or death.

Shuntaro Obi, Masao Omata

Pageof 2

Frequent Collaborators

2 joint publications

Tatsuo Kanda

2 joint publications

Hitoshi Mochizuki

2 joint publications

Masao Omata